Therapeutic bone replacement material
A biodegradable bone replacement material for the treatment of bone defects and delivery of antibiotic compounds, particularly for treating bone infections, comprising calcium sulfate hemihydrate, calcium sulfate dihydrate, an antibiotic mixture comprising a tetracycline compound and an ansamycin compound. Preferably, the ratio of calcium sulfate hemihydrate to calcium sulfate dihydrate is from 1:1 to about 3:1. Methods for treating, repairing or augmenting an osseous defect using the bone replacement material are also provided.
1 . A biodegradable bone replacement material comprising (a) calcium sulfate hemihydrate, (b) calcium sulfate dihydrate, (c) an antibiotic mixture comprising a tetracycline compound and an ansamycin compound, and (d) a mixing solution, wherein the ratio of (a) to (b) is from about 1:1 to about 3:1.
2 . A bone replacement material according to claim 1 , wherein the mixing solution is selected from the group consisting of citrates, tartrates, dibasic phosphate salts, and mixtures thereof.
3 . A bone replacement material according to claim 2 , wherein the mixing solution comprises potassium citrate and sodium phosphate.
4 . The bone replacement material according to claim 2 , wherein the tetracycline compound is selected from the group consisting of chlortetracycline, oxytetracycline, doxycycline, clomocycline, demeclocycline, guamecycline, lymecycline, meclocycline, tetracycline, penimepicycline, pipacycline, rolitetracycline, sancycline, minocycline, methacycline, and pharmaceutically acceptable salts, esters, and enantiomers thereof.
5 . The bone replacement material according to claim 4 , wherein the tetracycline compound is minocycline.
6 . The bone replacement material according to claim 1 , wherein the ansamycin compound is selected from the group consisting of geldanamycin, rifamide, rifampin. rifamycin, rifapentine, and rifaximin and pharmaceutically acceptable salts, esters, and enantioners thereof.
7 . The bone replacement material according to claim 6 , wherein the ansamysin compound is rifampin.
8 . The bone replacement material according to claim 1 , wherein the antibiotic mixture has a greater resorption rate in vivo than the calcium sulfate hemihydrate and calcium sulfate dihydrate.
9 . The bone replacement material according to claim 8 , wherein the antibiotic mixture has a release time of greater than or equal to three days.
10 . The bone replacement material according to claim 1 , wherein the bone replacement material further comprises an osteoinductive agent.
11 . The bone replacement material according to claim 10 , wherein the osteoinductive agent is selected from the group consisting of demineralized bone, demineralized bone matrix, bone morphogenetic proteins (BMP 1-17), insulin-like growth factor (IGF-1 & 2), transforming growth factor betal (TGF-β1), platelet derived growth factor (PDGF), beta-fibroblast growth factor (P-FGF), vascular endothelial growth factor (VEGF), osteocalcin, osteopontin, and combinations thereof.
12 . The bone replacement material according to claim 1 , wherein the material further comprises a radiopaque marker.
13 . The bone replacement material according to claim 12 , wherein the radiopaque marker is selected from the group consisting of barium sulfate, barium fluoride, barium polyacrylate, iodipamide, bismuth, lead, mercury, uranium, silver, gold, zirconium, titanium dioxide, chromium oxide, and combinations thereof.
14 . The bone replacement material according to claim 1 , wherein the material is in the form selected from the group consisting of a pellet, a bead, a granule, a powder, a chip, and a shaped object.
15 . A bone void filler comprising the bone replacement material in accordance with claim 1 .
16 . A dental prosthesis comprising the bone replacement material in accordance with claim 1 .
17 . An orthopedic prosthesis comprising the bone replacement material in accordance with claim 1 .
18 . A method of treating, repairing and augmenting a bone defect in osseous tissue, comprising applying to the site of the defect a bone replacement material, said material comprising
(a) calcium sulfate hemihydrate;
(b) calcium sulfate dihydrate;
(c) an antibiotic mixture comprising a tetracycline compound and an ansamycin compound; and
(d) a mixing solution,
wherein the ratio of (a) to (b) is from 1:1 to 3:1.
19 . A method according to claim 18 , wherein the mixing solution is selected from the group consisting of citrates, tartrates, dibasic phosphate salts, and mixtures thereof.
20 . A method according to claim 18 , wherein the antibiotic mixture comprises rifampin and minocycline.
21 . A method according to claim 18 , wherein said material further comprises one or more osteoinductive agents.
22 . A method according to claim 21 , wherein said osteoinductive agent is selected from the group consisting of demineralized bone, demineralized bone matrix, bone morphogenetic proteins (BMP 1-17), insulin-like growth factor (IGF-1 & 2), transforming growth factor betal (TGF-β1), platelet derived growth factor (PDGF), beta-fibroblast growth factor (P-FGF), vascular endothelial growth factor (VEGF), osteocalcin, osteopontin, and combinations thereof.
23 . A kit containing sterile components comprising calcium sulfate hemihydrate and calcium sulfate dihydrate, and instructions for use thereof to prepare a bone replacement material by mixing the calcium sulfate hemihydrate and the calcium sulfate dihydrate with an antibiotic mixture and a mixing solution.
24 . A kit according to claim 23 , further comprising an antibiotic mixture comprising a tetracycline compound and an ansamycin compound.
25 . A kit according to claim 23 , further comprising a mixing solution.